Orchestra BioMed Holdings Valuation
Is OBIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of OBIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate OBIO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate OBIO's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OBIO?
Key metric: As OBIO barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is OBIO's PB Ratio? | |
|---|---|
| PB Ratio | 4.7x |
| Book | US$46.22m |
| Market Cap | US$206.79m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 53.5x |
| Enterprise Value/EBITDA | -2.4x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does OBIO's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 11.4x | ||
DCTH Delcath Systems | 36.4x | 71.2% | US$314.9m |
CVRX CVRx | 5.5x | 17.1% | US$358.4m |
ZOM Zomedica | 0.6x | 23.3% | US$128.6m |
LUNG Pulmonx | 2.9x | 9.9% | US$253.5m |
OBIO Orchestra BioMed Holdings | 4.7x | 5.4% | US$206.8m |
Price-To-Book vs Peers: OBIO is good value based on its Price-To-Book Ratio (4.7x) compared to the peer average (11.4x).
Price to Book Ratio vs Industry
How does OBIO's PB Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Book vs Industry: OBIO is expensive based on its Price-To-Book Ratio (4.7x) compared to the US Medical Equipment industry average (2.5x).
Price to Book Ratio vs Fair Ratio
What is OBIO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 4.7x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate OBIO's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$5.77 | US$15.60 +170.4% | 14.4% | US$20.00 | US$14.00 | n/a | 5 |
| Nov ’25 | US$5.29 | US$15.60 +194.9% | 14.4% | US$20.00 | US$14.00 | n/a | 5 |
| Oct ’25 | US$4.90 | US$15.60 +218.4% | 14.4% | US$20.00 | US$14.00 | n/a | 5 |
| Sep ’25 | US$6.70 | US$15.60 +132.8% | 14.4% | US$20.00 | US$14.00 | n/a | 5 |
| Aug ’25 | US$6.85 | US$16.00 +133.6% | 14.7% | US$20.00 | US$14.00 | n/a | 4 |
| Jul ’25 | US$7.12 | US$16.33 +129.4% | 16.1% | US$20.00 | US$14.00 | n/a | 3 |
| Jun ’25 | US$6.93 | US$16.33 +135.7% | 16.1% | US$20.00 | US$14.00 | n/a | 3 |
| May ’25 | US$4.40 | US$16.33 +271.2% | 16.1% | US$20.00 | US$14.00 | n/a | 3 |
| Apr ’25 | US$4.95 | US$16.33 +230.0% | 16.1% | US$20.00 | US$14.00 | n/a | 3 |
| Mar ’25 | US$6.86 | US$16.33 +138.1% | 16.1% | US$20.00 | US$14.00 | n/a | 3 |
| Feb ’25 | US$7.50 | US$16.25 +116.7% | 14.0% | US$20.00 | US$14.00 | n/a | 4 |
| Jan ’25 | US$9.13 | US$17.00 +86.2% | 12.7% | US$20.00 | US$15.00 | n/a | 3 |
| Dec ’24 | US$6.81 | US$17.00 +149.6% | 12.7% | US$20.00 | US$15.00 | n/a | 3 |
| Nov ’24 | US$4.70 | US$20.33 +332.6% | 2.3% | US$21.00 | US$20.00 | US$5.29 | 3 |
| Oct ’24 | US$8.72 | US$20.33 +133.2% | 2.3% | US$21.00 | US$20.00 | US$4.90 | 3 |
| Sep ’24 | US$6.26 | US$20.33 +224.8% | 2.3% | US$21.00 | US$20.00 | US$6.70 | 3 |
| Aug ’24 | US$5.50 | US$20.33 +269.7% | 2.3% | US$21.00 | US$20.00 | US$6.85 | 3 |
| Jul ’24 | US$7.00 | US$20.33 +190.5% | 2.3% | US$21.00 | US$20.00 | US$7.12 | 3 |
| Jun ’24 | US$16.34 | US$20.33 +24.4% | 2.3% | US$21.00 | US$20.00 | US$6.93 | 3 |
| May ’24 | US$15.07 | US$18.67 +23.9% | 14.1% | US$21.00 | US$15.00 | US$4.40 | 3 |
| Apr ’24 | US$19.57 | US$18.67 -4.6% | 14.1% | US$21.00 | US$15.00 | US$4.95 | 3 |
| Mar ’24 | US$10.02 | US$17.50 +74.7% | 14.3% | US$20.00 | US$15.00 | US$6.86 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Elevance Health
US$93.6b
Operates as a health benefits company in the United States.
ELV
US$402.55
7D
0.5%
1Y
-15.9%
Centene
US$30.5b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
CNC
US$60.37
7D
5.1%
1Y
-18.8%
electroCore
US$64.0m
A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.
ECOR
US$11.21
7D
2.5%
1Y
101.6%